DoubleChecks

What was claimed

New Phase 3 trial proves personalized (neoantigen) cancer vaccines rev up immune response and work as a real treatment.

Our verdict

Needs caution

The recent Phase 3 showed a meaningful clinical benefit when the vaccine was added to pembrolizumab in high‑risk melanoma patients, which supports therapeutic activity, but this is one indication and does not constitute universal proof that all personalized neoantigen vaccines are effective or that they are approved as standard treatment across cancers. The phrasing 'New Phase 3 trial proves' suggests a single conclusive finding, but neoantigen vaccines are still in early clinical development with ongoing trials across multiple platforms and cancer types.

All 3 AI systems agree20 sources citedChecked Aug 23, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

The statement implies this is a singular, definitive breakthrough

Misleading80%
1 AI checked

Personalized neoantigen vaccines "work as a real treatment."

Misleading88%
All 2 AIs agree

Neoantigen vaccines rev up immune response

Verified90%
1 AI checked

A new Phase 3 trial proves personalized (neoantigen) cancer vaccines "rev up" the immune response.

Verified93%
2 of 4 AIs agree·ChatGPT: Misleading, Perplexity: Misleading

Verified against 20 sources

onlinelibrary.wiley.compubmed.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.govclinicaltrials.govpmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.govtandfonline.comsciencedirect.comtricisionbio.compmc.ncbi.nlm.nih.govsciencemediacentre.escell.compubmed.ncbi.nlm.nih.govaacr.orgpmc.ncbi.nlm.nih.govnature.comnature.comcancer.govnature.comrupress.org

Detailed Analysis

The claim is broadly supported in one important sense: recent phase 3 results for Moderna/Merck’s personalized mRNA neoantigen vaccine in melanoma reported significant recurrence-free and distant metastasis-free survival benefits. But the wording is overstated, because the evidence is from an announced interim analysis and an adjuvant setting, not a general proof that these vaccines "work as a real treatment" for cancer overall.[9] [11]

Why this verdict

  • The claim is broadly supported in one important sense: recent phase 3 results for Moderna/Merck’s personalized mRNA neoantigen vaccine in melanoma reported significant recurrence-free and distant metastasis-free survival benefits.
  • But the wording is overstated, because the evidence is from an announced interim analysis and an adjuvant setting, not a general proof that these vaccines "work as a real treatment" for cancer overall.[9] [11]

Claims checked

New Phase 3 trial proves personalized (neoantigen) cancer vaccines work as a real treatment.

Misleading90%
The phase 3 result is promising, but it is specific to one adjuvant melanoma regimen and was reported as a pre-specified interim analysis. It does not establish a universal, proven treatment for cancer overall.[9] [11] [13]

This claim may mislead readers without added context.

New Phase 3 trial proves personalized (neoantigen) cancer vaccines rev up immune response.

Verified91%
Recent studies and reviews show personalized neoantigen vaccines induce strong T-cell/immune responses, and the phase 3 melanoma trial announcement reported clinical efficacy endpoints were met.[9] [11] [16] [17]

What other AI think

The statement contains both accurate and misleading elements. Recent Phase 3 trial data does exist showing neoantigen vaccines can slow disease recurrence and boost immune responses. However, the claim overstates the evidence by suggesting vaccines "work as a real treatment" when most clinical development remains in early phases and efficacy is typically demonstrated in combination with other therapies, not as standalone treatments.

Why this verdict

  • The statement contains both accurate and misleading elements.
  • Recent Phase 3 trial data does exist showing neoantigen vaccines can slow disease recurrence and boost immune responses.
  • However, the claim overstates the evidence by suggesting vaccines "work as a real treatment" when most clinical development remains in early phases and efficacy is typically demonstrated in combination with other therapies, not as standalone treatments.

Claims checked

The statement implies this is a singular, definitive breakthrough

Misleading80%
The phrasing 'New Phase 3 trial proves' suggests a single conclusive finding, but neoantigen vaccines are still in early clinical development with ongoing trials across multiple platforms and cancer types.

This claim may mislead readers without added context.

Neoantigen vaccines work as a real treatment

Misleading85%
While Phase 3 data shows promise, most clinical development remains in early stages (Phase 1 dominant). Vaccines typically work best combined with immunotherapy (like checkpoint inhibitors), not as standalone treatments. The field is still developing.

This claim may mislead readers without added context.

Neoantigen vaccines rev up immune response

Verified90%
Multiple clinical trials demonstrate that neoantigen vaccines induce strong T-cell responses and immune activation against tumor antigens across various cancer types.
A randomized late-stage (Phase 3) trial recently reported a positive clinical benefit for a personalized mRNA neoantigen vaccine added to standard immunotherapy in melanoma. However the statement overgeneralizes from that single trial and frames the result as categorical proof and a broad claim about immune activation across cancers.

Why this verdict

  • A randomized late-stage (Phase 3) trial recently reported a positive clinical benefit for a personalized mRNA neoantigen vaccine added to standard immunotherapy in melanoma.
  • However the statement overgeneralizes from that single trial and frames the result as categorical proof and a broad claim about immune activation across cancers.

Claims checked

A new Phase 3 trial proves personalized (neoantigen) cancer vaccines "rev up" the immune response.

Misleading85%
A randomized Phase 3 result (Merck/Moderna) reported clinical benefit in melanoma and earlier and smaller studies show vaccine-induced T-cell responses, but saying the Phase 3 "proves" immune activation for all neoantigen vaccines overstates the evidence and generalizes beyond the specific trial and measurements.

This claim may mislead readers without added context.

Personalized neoantigen vaccines "work as a real treatment."

Misleading90%
The recent Phase 3 showed a meaningful clinical benefit when the vaccine was added to pembrolizumab in high‑risk melanoma patients, which supports therapeutic activity, but this is one indication and does not constitute universal proof that all personalized neoantigen vaccines are effective or that they are approved as standard treatment across cancers.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks